Sep 18, 2017
103PComparison of continuous measures across diagnostic PD-L1 assays using image analysis
T. Wiestler, M. Widmaier, J. Walker, C. Barker, M. Scott, F. Sekhavati, A. Budco, K. Schneider, K. Steele, M.C. Rebelatto , Annals of Oncology , DOI: 10.1093/annonc/mdx363.019
Background: Tumour programmed cell death ligand-1 (PD-L1) expression is a key biomarker in identifying patients who may have an enhanced response to non-small cell lung cancer treatment using anti-PD-1 (e.g. nivolumab and pembrolizumab) or anti-PD-L1 (e.g. atezolizumab and durvalumab). Each treatment is currently used in conjunction with an individual PD-L1...
Sep 14, 2017
Pluripotency Surveillance by Myc-Driven Competitive Elimination of Differentiating Cells
C. Díaz-Díaz, L. Fernandez de Manuel, D. Jimenez-Carretero, M. C. Montoya, C. Clavería, M. Torres , Developmental Cell , DOI: 10.1016/j.devcel.2017.08.011
The mammalian epiblast is formed by pluripotent cells able to differentiate into all tissues of the new individual. In their progression to differentiation, epiblast cells and their in vitro counterparts, embryonic stem cells (ESCs), transit from naive pluripotency through a differentiation-primed pluripotent state. During these events, epiblast cells and ESCs are...
Sep 14, 2017
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
H. Jouihan, S. Will, S. Guionaud, M. L.Boland, S. Oldham, P.Ravn, A. Celeste, J. L.Trevaskis , Science Direct , DOI: 10.1016/j.molmet.2017.09.001
Objective: Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects of co-administration of a GLP-1R agonist, IP118, with FXR agonist obeticholic acid...
Sep 9, 2017
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
J. M. Saunus, C. E. Smart, J. R. Kutasovic, R. L. Johnston, P. Kalita-de Croft, M. Miranda, E. N. Rozali, A. C. Vargas, L. E. Reid, E. Lorsy, S. Cocciardi, T. Seidens, A. E. McCart Reed, A. J. Dalley, L. F. Wockner, J. Johnson, D. Sarkar, M. E. Askarian-Amiri, P. T. Simpson, K. K. Khanna, G. Chenevix-Trench, F. Al-Ejeh, S. R. Lakhani , Breast Cancer Research and Treatment , DOI: 10.1007/s10549-017-4496-x
Purpose: Cell lines are extremely useful tools in breast cancer research. Their key benefits include a high degree of control over experimental variables and reproducibility. However, the advantages must be balanced against the limitations of modelling such a complex disease in vitro. Informed selection of cell line(s) for a given...
Sep 5, 2017
Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas
J. B. Permuth, D.-T. Chen, S. J. Yoder, J. Li, A. T. Smith, J. W. Choi, J. Kim, Y. Balagurunathan, K. Jiang, D. Coppola, B. A. Centeno, J. Klapman, P. Hodul, F. A. Karreth, J. G. Trevino, N. Merchant, A. Magliocco, M. P. Malafa, R. Gillies , Scientific Reports , DOI: 10.1038/s41598-017-09754-5
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease that lacks effective biomarkers for early detection. We hypothesized that circulating long non-coding RNAs (lncRNAs) may act as diagnostic markers of incidentally-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/histological classification. Using NanoString nCounter® technology,...